Cargando…

Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)

AIMS: Patients with atrial fibrillation (AF) are at increased risk of stroke. Betrixaban is a novel oral factor Xa inhibitor administered once daily, mostly excreted unchanged in the bile and with low (17%) renal excretion. METHODS AND RESULTS: Patients with AF and more than one risk factor for stro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Connolly, Stuart J., Eikelboom, John, Dorian, Paul, Hohnloser, Stefan H., Gretler, Daniel D., Sinha, Uma, Ezekowitz, Michael D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2013
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659305/ https://www.ncbi.nlm.nih.gov/pubmed/23487517 http://dx.doi.org/10.1093/eurheartj/eht039

Ejemplares similares

Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism
por: Chan, Noel C, et al.
Publicado: (2015)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Pharmacological properties of betrixaban
por: Huisman, Menno V, et al.
Publicado: (2018)

Comparative analysis and meta-analysis of major clinical trials with oral factor Xa inhibitors versus warfarin in atrial fibrillation
por: Nunes, José Pedro L, et al.
Publicado: (2014)

Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study
por: Calkins, Hugh, et al.
Publicado: (2019)

Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES
por: Benz, Alexander P., et al.
Publicado: (2021)

Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation
por: Hijazi, Ziad, et al.
Publicado: (2020)

Direct oral anti-Xa anticoagulants versus warfarin in newly diagnosed atrial fibrillation and CKD: the Korean National Health Insurance Data
por: Kee, Youn Kyung, et al.
Publicado: (2023)

Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic
por: Lee, Siew Ling, et al.
Publicado: (2021)

Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation
por: Marcatto, Leiliane Rodrigues, et al.
Publicado: (2016)

Time in Therapeutic Range Using a Nomogram for Dose Adjustment of Warfarin in Patients on Hemodialysis With Atrial Fibrillation
por: Defoe, Kimberly, et al.
Publicado: (2021)

Warfarin and atrial fibrillation: from ideal to real the warfarin affaire
por: Molteni, Mauro, et al.
Publicado: (2014)

The use of warfarin in veterans with atrial fibrillation
por: Bravata, Dawn M, et al.
Publicado: (2004)

Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation
por: Pol, Tymon, et al.
Publicado: (2021)

Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study
por: Verdecchia, Paolo, et al.
Publicado: (2018)

Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation
por: Stoll, Svenja, et al.
Publicado: (2020)

Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation
por: Jansson, M., et al.
Publicado: (2023)

Betrixaban for prevention of venous thromboembolism in acute medically ill patients
por: Beyer-Westendorf, Jan, et al.
Publicado: (2018)

Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation
por: Williams, Brent A., et al.
Publicado: (2017)

Efficacy and Safety of Direct Factor Xa Inhibitors Versus Warfarin in Prevention of Primary and Secondary Ischemic Strokes in Non-Valvular Atrial Fibrillation: A Literature Review
por: Emamy, Mina, et al.
Publicado: (2020)

Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE‐LY Trial
por: Hijazi, Ziad, et al.
Publicado: (2019)

Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study
por: McAlister, Finlay A., et al.
Publicado: (2020)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
por: de Padua Mansur, Antonio, et al.
Publicado: (2012)

Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the ATHENA study
por: Blomström‐Lundqvist, Carina, et al.
Publicado: (2020)

Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
por: Nelson, Winnie W., et al.
Publicado: (2014)

Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study
por: Torp-Pedersen, Christian, et al.
Publicado: (2011)

Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
por: Jackson, Larry R., et al.
Publicado: (2018)

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019)

Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction
por: Szummer, Karolina, et al.
Publicado: (2017)

Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study
por: Hohnloser, Stefan H., et al.
Publicado: (2019)

Association of GGCX gene polymorphism with warfarin dose in atrial fibrillation population in Xinjiang
por: Kamali, Xiayizha, et al.
Publicado: (2013)

Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients
por: Cohen, Alexander T
Publicado: (2018)

ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation
por: Kaba, Riyaz A, et al.
Publicado: (2013)

Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study
por: Halvorsen, Sigrun, et al.
Publicado: (2021)

Lower dose direct oral anticoagulation or warfarin in atrial fibrillation. Which one is the best when time on therapeutic range information is available?
por: Luojus, A, et al.
Publicado: (2023)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014)

A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score
por: Hijazi, Ziad, et al.
Publicado: (2018)

Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study
por: Wu, Cynthia, et al.
Publicado: (2015)

Initiation and Persistence with Warfarin Therapy in Atrial Fibrillation According to Ethnicity
por: Hansen, Carolina Malta, et al.
Publicado: (2012)

Improving outpatient warfarin use for hospitalized patients with atrial fibrillation
por: Touchette, Daniel R., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_lqopiki9j0mjbq8og33jugjp5c